Role of antiestrogens and aromatase inhibitors in breast cancer treatment

被引：13

作者：

Bentrem, DJ ^{[1
]}

Jordan, VC ^{[1
]}

机构：

[1] Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Lynn Sage Breast Canc Res Program,Dept Surg, Chicago, IL 60611 USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2002年 / 14卷 / 01期

关键词：

D O I：

10.1097/00001703-200202000-00002

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

This review explores the recent experience with, and the basis for, the use of selective estrogen receptor modulators to treat and prevent breast cancer. As new agents are unveiled, they, will continue to be tested against tamoxifen. A number of new selective estrogen receptor modulators are in clinical development in an attempt to decrease the unwanted effects of tamoxifen. Raloxifene holds the promise of treating osteoporosis with the beneficial side effect of breast cancer prevention. Additionally, two different classes of hormonal agents, the aromatase inhibitors and estrogen receptor down-regulators, which have no estrogen-like properties at any site, appear to be promising new treatments for advanced breast cancer.

引用

页码：5 / 12

页数：8

共 60 条

[21] Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J].

Fisher, B ;

Dignam, J ;

Bryant, J ;

DeCillis, A ;

Wickerham, DL ;

Wolmark, N ;

Costantino, J ;

Redmond, C ;

Fisher, ER ;

Bowman, DM ;

Deschenes, L ;

Dimitrov, NV ;

Margolese, RG ;

Robidoux, A ;

Shibata, H ;

Terz, J ;

Paterson, AHG ;

Feldman, MI ;

Farrar, W ;

Evans, J ;

Lickley, HL .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1529-1542

[22] SYSTEMIC THERAPY IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER - A COMMENTARY BASED ON 2 NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) CLINICAL-TRIALS [J].

FISHER, B ;

REDMOND, C ;

WICKERHAM, DL ;

WOLMARK, N ;

BOWMAN, D ;

COUTURE, J ;

DIMITROV, NV ;

MARGOLESE, R ;

LEGAULTPOISSON, S ;

ROBIDOUX, A .

ANNALS OF INTERNAL MEDICINE, 1989, 111 (09) :703-712

[23] THE MECHANISM OF ICI-164,384 ANTIESTROGENICITY INVOLVES RAPID LOSS OF ESTROGEN-RECEPTOR IN UTERINE TISSUE [J].

GIBSON, MK ;

NEMMERS, LA ;

BECKMAN, WC ;

DAVIS, VL ;

CURTIS, SW ;

KORACH, KS .

ENDOCRINOLOGY, 1991, 129 (04) :2000-2010

[24] Aromatase inhibitors in the treatment and prevention of breast cancer [J].

Goss, PE ;

Strasser, K .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :881-894

[25]

GOTTARDIS MM, 1990, CANCER RES, V50, P3189

[26]

GOTTARDIS MM, 1988, CANCER RES, V48, P5183

[27]

GOTTARDIS MM, 1989, CANCER RES, V49, P4090

[28]

Gradishar W, 2000, CANCER, V88, P2047, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO

[29]

2-E

[30] RANDOMIZED COMPARISON OF TAMOXIFEN AND 2 SEPARATE DOSES OF TOREMIFENE IN POSTMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER [J].

HAYES, DF ;

VANZYL, JA ;

HACKING, A ;

GOEDHALS, L ;

BEZWODA, WR ;

MAILLIARD, JA ;

JONES, SE ;

VOGEL, CL ;

BERRIS, RF ;

SHEMANO, I ;

SCHOENFELDER, J .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2556-2566

← 1 2 3 4 5 6 →